R Vandermeer

819 total citations
15 papers, 322 citations indexed

About

R Vandermeer is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, R Vandermeer has authored 15 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in R Vandermeer's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). R Vandermeer is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). R Vandermeer collaborates with scholars based in Canada, United States and Netherlands. R Vandermeer's co-authors include Peter Ellis, Jan Kleibeuker, Desirée Hao, Richard B. Lanman, Lesli A. Kiedrowski, Doreen A. Ezeife, Scott A. Laurie, Janessa Laskin, Lisa W. Le and Frances A. Shepherd and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

R Vandermeer

15 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R Vandermeer Canada	5	126	116	77	64	51	15	322
C Couillault France	9	142 1.1×	103 0.9×	107 1.4×	45 0.7×	119 2.3×	13	437
Sophie Perry United Kingdom	6	69 0.5×	73 0.6×	51 0.7×	73 1.1×	29 0.6×	11	293
Wataru Saitoh Japan	13	141 1.1×	156 1.3×	164 2.1×	60 0.9×	17 0.3×	16	420
James Thomas United Kingdom	7	94 0.7×	60 0.5×	55 0.7×	56 0.9×	31 0.6×	24	316
Amanda Nogueira Belgium	4	134 1.1×	242 2.1×	58 0.8×	33 0.5×	35 0.7×	6	406
K. Yamazaki Japan	8	81 0.6×	175 1.5×	52 0.7×	63 1.0×	23 0.5×	34	338
Perminder Phull United Kingdom	10	268 2.1×	217 1.9×	59 0.8×	29 0.5×	109 2.1×	31	531
Dawn Q. Chong Singapore	8	86 0.7×	29 0.3×	77 1.0×	60 0.9×	55 1.1×	12	352
Lili Lu China	10	192 1.5×	75 0.6×	65 0.8×	50 0.8×	23 0.5×	33	365
Alessandro Mannucci Italy	8	215 1.7×	66 0.6×	65 0.8×	70 1.1×	99 1.9×	24	309

Countries citing papers authored by R Vandermeer

Since Specialization

Citations

This map shows the geographic impact of R Vandermeer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Vandermeer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Vandermeer more than expected).

Fields of papers citing papers by R Vandermeer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Vandermeer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Vandermeer. The network helps show where R Vandermeer may publish in the future.

Co-authorship network of co-authors of R Vandermeer

This figure shows the co-authorship network connecting the top 25 collaborators of R Vandermeer. A scholar is included among the top collaborators of R Vandermeer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Vandermeer. R Vandermeer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Feng, Jiao, Lawson Eng, Frances A. Shepherd, et al.. (2024). 71P A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NCT03991819). ESMO Open. 9. 102650–102650. 1 indexed citations

Eng, Lawson, Frances A. Shepherd, Swati Kulkarni, et al.. (2023). Abstract CT206: A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). Cancer Research. 83(8_Supplement). CT206–CT206. 2 indexed citations

Ezeife, Doreen A., Eldon Spackman, Rosalyn A. Juergens, et al.. (2022). The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 14. 27 indexed citations

Ezeife, Doreen A., Eldon Spackman, Rosalyn A. Juergens, et al.. (2021). OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(10). S876–S876. 3 indexed citations

Hao, Desirée, Janessa Laskin, Scott A. Laurie, et al.. (2021). P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System. Journal of Thoracic Oncology. 16(3). S689–S689. 6 indexed citations

Laurie, Scott A., Jason Agulnik, Desirée Hao, et al.. (2020). 1195P The value of detecting resistance through liquid biopsy. Annals of Oncology. 31. S786–S787. 1 indexed citations

Juergens, Rosalyn A., Doreen A. Ezeife, Janessa Laskin, et al.. (2020). Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. Journal of Clinical Oncology. 38(15_suppl). 3546–3546. 2 indexed citations

Vandermeer, R, S. Chambers, Alje P. van Dam, et al.. (2015). Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?. Current Oncology. 22(4). 272–278. 8 indexed citations

Ellis, Peter & R Vandermeer. (2011). Delays in the diagnosis of lung cancer.. PubMed. 3(3). 183–8. 136 indexed citations

10.

Vandermeer, R, S. Dimitry, Andrew Arnold, & Peter Ellis. (2006). Delays in diagnosis and initiating treatment for patients with lung cancer. Journal of Clinical Oncology. 24(18_suppl). 6102–6102. 1 indexed citations

11.

Kleibeuker, Jan, et al.. (1996). Calcium in milk products precipitates intestinal fatty acids and secondary bile acids and thus inhibits colonic cytotoxicity in humans.. PubMed. 56(14). 3270–5. 130 indexed citations

12.

Vandermeer, R, et al.. (1996). Bile acid profile and cytotoxicity of fecal water after proximal or distal hemicolectomy. Data Archiving and Networked Services (DANS). 110(4). 1 indexed citations

13.

Lapré, J.A., et al.. (1994). CALCIUM IN MILK-PRODUCTS PRECIPITATES INTESTINAL SURFACTANTS AND INHIBITS LUMINAL CYTOLYTIC ACTIVITY IN HEALTHY-SUBJECTS. Data Archiving and Networked Services (DANS). 106(4). 2 indexed citations

14.

Kleibeuker, JH, et al.. (1993). DIETARY CALCIUM IN MILK-PRODUCTS INHIBITS CYTOLYTIC ACTIVITY OF FECAL WATER IN HEALTHY-VOLUNTEERS. Data Archiving and Networked Services (DANS). 104(4). 1 indexed citations

15.

Vandermeer, R, et al.. (1988). SHORT-TERM EFFECTS OF DIETARY CALCIUM SUPPLEMENTATION ON FECAL EXCRETION OF MINERALS AND BILE-ACIDS. Data Archiving and Networked Services (DANS). 94(5). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact